While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.
The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.